Single Domain Antibodies for Complement Regulation
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/EP2019/065206, filed Jun 11, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,240,912 | Methods of Treating Complement-Mediated Disease In force · High confidence | Aarhus Universitet | In force | High confidence | ||
| US 12,258,416 | Bispecific Constructs for Target and Complement Engagement In force · Low confidence | Aarhus Universitet | In force | Low confidence | ||
| US 12,110,321 | Single Domain Antibodies for Complement Regulation In force · High confidence | Aarhus Universitet | In force | High confidence | ||
| Application 19/045,685 | Bispecific Constructs for Target and Complement Engagement Pending Not granted | Aarhus Universitet | Pending | Not granted | ||
| Application 19/045,689 | Methods of Treating Complement-Mediated Disease Pending Not granted | Aarhus Universitet | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Aarhus Universitet.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.